A new payment-by-results method for determining the fair price of new oncological drugs
DOI:
https://doi.org/10.33393/grhta.2015.332Keywords:
Payment-by-results, Progression-free survival, Overall survival, Survival distributionsAbstract
The high prices of new cancer drugs are likely to undermine national health services sustainability. As a solution to this problem, the “payment-by-results” method was proposed and nowadays this approach is commonly implemented by national drug agencies: the drug manufacturer is set to refund to the National Health Service the price of the drug if the benefits expected for the patient are not achieved. Based on the payment-by-results approach, we developed a new and easy to implement model, that can set a fair price, so that neither industry, nor National Health Service can obtain an undue gain. Obviously, this price can be modified by adjusting refund amounts to new healthcare and market conditions.Downloads
Download data is not yet available.
Downloads
Published
2015-10-07
How to Cite
Ballatori, E., Ferrante, L., Ruggeri, B., & Roila, F. (2015). A new payment-by-results method for determining the fair price of new oncological drugs. Global and Regional Health Technology Assessment, 2(2), 97–100. https://doi.org/10.33393/grhta.2015.332
Issue
Section
Original Research Articles
License
Authors contributing to Global & Regional Health Technology Assessment agree to publish their articles under the CC-BY-NC 4.0 license, which allows third parties to re-use the work without permission as long as the work is properly referenced and the use is non-commercial.
